Acute antibiotic use in cystic fibrosis clinical trials: Does it affect our assessment of clinical efficacy?

The Lancet Respiratory Medicine

Volumn 1, Issue 2, 2013, Pages 98-99

  Mayer Hamblett, Nicole ^a   Ratjen, Felix ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN;

CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; LETTER; LUNG DISEASE; LUNG FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; MEDICATION THERAPY MANAGEMENT; RESPIRATORY SYSTEM; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84880044504     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70013-4     Document Type: Letter

References (10)

1. Hoffman LR, Ramsey BW Cystic fibrosis therapeutics: the road ahead. Chest 2013, 143:207-213.
2. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010, 182:298-306.
3. Goss CH, Burns JL Exacerbations in cystic fibrosis-1: epidemiology and pathogenesis. Thorax 2007, 62:360-367.
4. Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials: Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011, 10(suppl 2):S79-S81.
5. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
6. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
7. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
8. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165:847-856.
9. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012, 307:2269-2277.
10. Goss CH, Quittner AL Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007, 4:378-386.